30 μM). Of these compounds, seven were specific for CRC cells, and six were effective in all CRC cell lines tested. Treatment with traditional phytocannabinoids (THC or CBD) was either ineffective or much less potent and only partially efficacious. Treatment with antagonists for the known cannabinoid receptors (alone or in combination) failed to block the activity of the most potent of identified compounds. Conclusion: We identified three families of cannabinoid compounds that reduce CRC cell viability through a noncanonical receptor mechanism. Future modification of these compounds may lead to the development of novel therapies to treat this disease.
CBD; THC; colorectal cancer; synthetic cannabinoids
PMID: 30671539 PMCID: PMC6340378 DOI: 10.1089/can.2018.0065 ShareConflict of interest statement
The authors have no conflicts of interest, and no competing financial interests exist.
Supplemental Content —
View the Original article